Cargando…

Astragaloside IV, as a potential anticancer agent

Cancer is a global intractable disease, and its morbidity and mortality are increasing year by year in developing countries. Surgery and chemotherapy are often used to treat cancer, but they result in unsatisfactory outcomes, such as severe side effects and drug resistance. With the accelerated mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Dongqin, Li, Wenjie, Tang, Ce, Jiang, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981805/
https://www.ncbi.nlm.nih.gov/pubmed/36874003
http://dx.doi.org/10.3389/fphar.2023.1065505
_version_ 1784900188465266688
author Xia, Dongqin
Li, Wenjie
Tang, Ce
Jiang, Juan
author_facet Xia, Dongqin
Li, Wenjie
Tang, Ce
Jiang, Juan
author_sort Xia, Dongqin
collection PubMed
description Cancer is a global intractable disease, and its morbidity and mortality are increasing year by year in developing countries. Surgery and chemotherapy are often used to treat cancer, but they result in unsatisfactory outcomes, such as severe side effects and drug resistance. With the accelerated modernization of traditional Chinese medicine (TCM), an increasing body of evidence has shown that several TCM components have significant anticancer activities. Astragaloside IV (AS-IV) is considered the main active ingredient of the dried root of Astragalus membranaceus. AS-IV exhibits various pharmacological effects, such as anti-inflammatory, hypoglycemic, antifibrotic, and anticancer activities. AS-IV possesses a wide range of activities, such as the modulation of reactive oxygen species-scavenging enzyme activities, participation in cell cycle arrest, induction of apoptosis and autophagy, and suppression of cancer cell proliferation, invasiveness, and metastasis. These effects are involved in the inhibition of different malignant tumors, such as lung, liver, breast, and gastric cancers. This article reviews the bioavailability, anticancer activity, and mechanism of AS-IV and provides suggestions for further research of this TCM.
format Online
Article
Text
id pubmed-9981805
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99818052023-03-04 Astragaloside IV, as a potential anticancer agent Xia, Dongqin Li, Wenjie Tang, Ce Jiang, Juan Front Pharmacol Pharmacology Cancer is a global intractable disease, and its morbidity and mortality are increasing year by year in developing countries. Surgery and chemotherapy are often used to treat cancer, but they result in unsatisfactory outcomes, such as severe side effects and drug resistance. With the accelerated modernization of traditional Chinese medicine (TCM), an increasing body of evidence has shown that several TCM components have significant anticancer activities. Astragaloside IV (AS-IV) is considered the main active ingredient of the dried root of Astragalus membranaceus. AS-IV exhibits various pharmacological effects, such as anti-inflammatory, hypoglycemic, antifibrotic, and anticancer activities. AS-IV possesses a wide range of activities, such as the modulation of reactive oxygen species-scavenging enzyme activities, participation in cell cycle arrest, induction of apoptosis and autophagy, and suppression of cancer cell proliferation, invasiveness, and metastasis. These effects are involved in the inhibition of different malignant tumors, such as lung, liver, breast, and gastric cancers. This article reviews the bioavailability, anticancer activity, and mechanism of AS-IV and provides suggestions for further research of this TCM. Frontiers Media S.A. 2023-02-17 /pmc/articles/PMC9981805/ /pubmed/36874003 http://dx.doi.org/10.3389/fphar.2023.1065505 Text en Copyright © 2023 Xia, Li, Tang and Jiang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Xia, Dongqin
Li, Wenjie
Tang, Ce
Jiang, Juan
Astragaloside IV, as a potential anticancer agent
title Astragaloside IV, as a potential anticancer agent
title_full Astragaloside IV, as a potential anticancer agent
title_fullStr Astragaloside IV, as a potential anticancer agent
title_full_unstemmed Astragaloside IV, as a potential anticancer agent
title_short Astragaloside IV, as a potential anticancer agent
title_sort astragaloside iv, as a potential anticancer agent
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981805/
https://www.ncbi.nlm.nih.gov/pubmed/36874003
http://dx.doi.org/10.3389/fphar.2023.1065505
work_keys_str_mv AT xiadongqin astragalosideivasapotentialanticanceragent
AT liwenjie astragalosideivasapotentialanticanceragent
AT tangce astragalosideivasapotentialanticanceragent
AT jiangjuan astragalosideivasapotentialanticanceragent